VYNE Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

De winst van VYNE Therapeutics zal naar verwachting dalen met 15.6% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 64.5% per jaar. De winst per aandeel zal naar verwachting afnemen met 7.9% per jaar.

Belangrijke informatie

-15.6%

Groei van de winst

-7.90%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	14.6%
Inkomstengroei	64.5%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	08 May 2026

Recente toekomstige groei-updates

Recent updates

Analyseartikel • Jun 27

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics press release (NASDAQ:VYNE): Q2 Non-GAAP EPS of -$0.13 beats by $0.02. Revenue of $0.13M (-55.2% Y/Y) beats by $0.03M. As of June 30, 2022, VYNE had cash and cash equivalents of $42.8 million. Shares -4% PM.

Analyseartikel • Jul 02

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analyseartikel • Mar 19

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Jan 13

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Sales of Vyne Therapeutic's minocycline products were just $4 million last quarter which may hamper the company’s ability to sell or license the franchise. Vyne has shifted its focus from marketing the approved minocycline products to 3 pre-clinical assets which require substantial cash and expose investors to a high degree of clinical risk. The largest institutional shareholder has sold most of their position. The cash position is sufficient only through Q2 of 2022 and significant dilution is likely.

Analyseartikel • Dec 03

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyseartikel • Aug 13

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Market forces rained on the parade of VYNE Therapeutics Inc. ( NASDAQ:VYNE ) shareholders today, when the analysts...

Seeking Alpha • Jun 30

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

VYNE stock has depreciated by 65% in the last 3 months. There are no overwhelmingly critical factors behind this. The market, and smart money, just seem to dislike the stock.

Winst- en omzetgroeiprognoses

NasdaqCM:VYNE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2028	7	-88	-121	N/A	2
12/31/2027	N/A	-66	-81	N/A	2
12/31/2026	N/A	-50	-56	N/A	2
3/31/2026	0	-22	-26	-26	N/A
12/31/2025	1	-27	-33	-33	N/A
9/30/2025	1	-34	-38	-38	N/A
6/30/2025	0	-39	-40	-40	N/A
3/31/2025	1	-42	-38	-37	N/A
12/31/2024	1	-40	-34	-34	N/A
9/30/2024	0	-34	-30	-30	N/A
6/30/2024	0	-28	-27	-27	N/A
3/31/2024	0	-29	-28	-28	N/A
12/31/2023	0	-28	-25	-25	N/A
9/30/2023	0	-29	-25	-25	N/A
6/30/2023	0	-33	-27	-27	N/A
3/31/2023	0	-31	-26	-26	N/A
12/31/2022	0	-34	-29	-29	N/A
9/30/2022	1	-35	-34	-34	N/A
6/30/2022	1	-40	-45	-45	N/A
3/31/2022	1	-42	-53	-53	N/A
12/31/2021	1	-44	-56	-56	N/A
9/30/2021	5	-59	-72	-72	N/A
6/30/2021	8	-69	-78	-78	N/A
3/31/2021	19	-226	-97	-97	N/A
12/31/2020	21	-256	-137	-137	N/A
9/30/2020	17	-270	-134	-134	N/A
6/30/2020	14	-269	-133	-132	N/A
3/31/2020	2	-120	-110	-109	N/A
12/31/2019	0	-95	N/A	-73	N/A
9/30/2019	1	-71	N/A	-62	N/A
6/30/2019	2	-64	N/A	-62	N/A
3/31/2019	3	-63	N/A	-62	N/A
12/31/2018	4	-74	N/A	-69	N/A
9/30/2018	4	-77	N/A	-70	N/A
6/30/2018	4	-80	N/A	-69	N/A
3/31/2018	4	-77	N/A	-64	N/A
12/31/2017	4	-66	N/A	-53	N/A
9/30/2017	4	-59	N/A	-53	N/A
6/30/2017	6	-47	N/A	-36	N/A
3/31/2017	6	-39	N/A	-32	N/A
12/31/2016	6	-29	N/A	-27	N/A
9/30/2016	4	-24	N/A	-18	N/A
6/30/2016	2	-21	N/A	-19	N/A
3/31/2016	1	-18	N/A	-18	N/A
12/31/2015	1	-17	N/A	-12	N/A
9/30/2015	4	-11	N/A	-10	N/A
6/30/2015	4	-16	N/A	-7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat VYNE de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat VYNE de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat VYNE de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat VYNE volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat VYNE volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van VYNE naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/06/08 08:25
Aandelenkoers aan het einde van de dag	2026/06/05 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

VYNE Therapeutics Inc. wordt gevolgd door 11 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Douglas Tsao	Barclays
Jason Matthew Gerberry	BofA Global Research
Louise Chen	Guggenheim Securities, LLC

VYNE Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates upgraded to US$0.59 loss

Price target decreased by 11% to US$5.50

Consensus EPS estimates fall by 19%

Consensus revenue estimates increase by 250%

Consensus revenue estimates fall by 20%

Consensus EPS estimates fall by 13%

Recent updates

First quarter 2026 earnings released: US$0.084 loss per share (vs US$0.20 loss in 1Q 2025)

VYNE Therapeutics Inc. Receives an Additional 180 Calendar Days Extension to Regain Compliance with the Minimum Bid Price Requirement

Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. (NasdaqCM:VYNE) in a reverse merger transaction.

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2025

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Notice of Non-Compliance with Nasdaq Listing Requirements

Insufficient new directors

First quarter 2025 earnings released: US$0.20 loss per share (vs US$0.15 loss in 1Q 2024)

Consensus EPS estimates upgraded to US$0.59 loss

New major risk - Market cap size

Price target decreased by 11% to US$5.50

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Consensus EPS estimates fall by 19%

VYNE Therapeutics Inc. Provides Program Update on Oral BET inhibitor VYN202

We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Consensus revenue estimates increase by 250%

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

VYNE Therapeutics Provides Update on VYN202 Program

Consensus revenue estimates fall by 20%

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Inc. Therapeutics Reports Positive Top-Line Phase 1A MAD Data for VYN202, Its Novel BD2-Selective Bet Inhibitor

Consensus EPS estimates fall by 13%

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Consensus revenue estimates increase by 50%, EPS downgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202

VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Consensus EPS estimates upgraded to US$0.81 loss

First quarter 2024 earnings released: US$0.15 loss per share (vs US$1.72 loss in 1Q 2023)

Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Lead Independent Director recently bought US$51k worth of stock

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

New major risk - Share price stability

Price target increased by 21% to US$16.50

New major risk - Market cap size

Consensus revenue estimates increase by 60%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

First quarter 2023 earnings released: US$1.72 loss per share (vs US$2.83 loss in 1Q 2022)

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Full year 2022 earnings released

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. announced that it has received $0.3 million in funding

VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.00